ArticleRheumatology and therapy2026
Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05662241 (A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIgG4-related disease (IgG4-RD) is a chronic, multiorgan fibroinflammatory condition characterized by recurring flares that can lead to progressive organ damage and failure, impaired quality of life, and death. Glucocorticoids (GCs) remain the primary therapy despite their significant toxicity. Obexelimab is a humanized, bifunctional, monoclonal antibody designed to inhibit B cells by co-engaging CD19 and FcγRIIb (CD32b), mimicking natural inhibitory signaling triggered by antigen-antibody complexes. Following promising phase 2 results that demonstrated clinical improvement in 93% of patients with IgG4-RD, the phase 3 INDIGO trial was initiated.
methodsINDIGO is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of obexelimab in patients with IgG4-RD. The trial has enrolled adult patients ≥ 18 years old with active IgG4-RD meeting the 2019 ACR/EULAR classification criteria (score ≥ 20). Following standardized GC induction, patients are randomized 1:1 to weekly subcutaneous obexelimab 250 mg or placebo for 52 weeks. An independent adjudication committee (AC) ensures consistent application of IgG4-RD classification and organ-specific flare criteria developed for the trial. PLANNED OUTCOMES: The primary endpoint is time to first IgG4-RD flare requiring initiation of rescue therapy as determined by both the investigator and AC. Key secondary endpoints are time to first investigator-determined flare requiring rescue therapy, number of investigator- and AC-determined flares requiring rescue therapy, proportion of patients achieving complete remission, and cumulative dose of GC rescue therapy for active IgG4-RD through Week 52.
conclusionThe INDIGO trial achieved its global enrollment goal with 194 patients, making it the largest phase 3 trial in IgG4-RD to date and providing 90% power to detect a clinically meaningful reduction in flare risk. This trial will provide critical evidence on B-cell inhibition as a treatment strategy for IgG4-RD and assess obexelimab as a potential steroid-sparing option to address significant unmet needs of this patient population.
trial registrationNCT05662241.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.